# Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

> **NCT00082875** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Stage III Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** cilengitide
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00082875
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082875, "Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00082875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*